Skip to main content

Advertisement

Log in

Long-Term Results of a Multi-Institutional Randomized Trial Comparing Prognostic Factors and Surgical Results for Intermediate Thickness Melanomas (1.0 to 4.0 mm)

  • Original Article
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Balch CM, Murad TM, Soong SJ, Ingalls AL, Halpern NB, Maddox WA. A multifactorial analysis of melanoma: prognostic histopathological features comparing Clark’s and Breslow’s staging methods. Ann Surg 1978;188:732–742.

    PubMed  CAS  Google Scholar 

  2. Breslow A. Tumor thickness, level of invasion and node dissection in stage I cutaneous melanoma. Ann Surg 1975;182:572–575.

    PubMed  CAS  Google Scholar 

  3. Reintgen DS, Cox EG, McCarty KSJ, Vollmer RT, Seigler HF. Efficacy of elective lymph node dissection in patients with intermediate thickness primary melanoma. Ann Surg 1983;198:379–385.

    PubMed  CAS  Google Scholar 

  4. Balch CM, Soong SJ, Milton GW, et al. A comparison of prognostic factors and surgical results in 1,786 patients with localized (stage I) melanoma treated in Alabama, USA, and New South Wales, Australia. Ann Surg 1982;196:677–684.

    PubMed  CAS  Google Scholar 

  5. Wanebo HJ, Fortner JG, Woodruff J, MacLean B, Binkowski E. Selection of the optimum surgical treatment of stage I melanoma by depth of microinvasion: use of the combined microstage technique (Clark-Breslow). Ann Surg 1975;182:302–314.

    PubMed  CAS  Google Scholar 

  6. Balch CM, Murad TM, Soong SJ, Ingalls AL, Richards PC, Maddox WA. Tumor thickness as a guide to surgical management of clinical stage I melanoma patients. Cancer 1979;43:883–888.

    PubMed  CAS  Google Scholar 

  7. Balch CM, Soong SJ, Murad TM, Ingalls AL, Maddox WA. A multifactorial analysis of melanoma. II. Prognostic factors in patients with stage I (localized) melanoma. Surgery 1979;86:343–351.

    PubMed  CAS  Google Scholar 

  8. Balch CM, Soong SJ, Bartolucci AA, et al. Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann Surg 1996;224:255–263.

    PubMed  CAS  Google Scholar 

  9. Balch CM, Urist MM, Karakousis CP, et al. Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1 to 4 mm): results of a multi-institutional randomized surgical trial. Ann Surg 1993;218:262–267.

    PubMed  CAS  Google Scholar 

  10. Zelen M. A new design for randomized clinical trials. N Engl J Med 1979;300:1242–1245.

    Article  CAS  PubMed  Google Scholar 

  11. Veronesi U, Adamus J, Bandiera DC, et al. Inefficacy of immediate node dissection in stage I melanoma of the limbs. N Engl J Med 1977;297:627–630.

    Article  PubMed  CAS  Google Scholar 

  12. Sim FH, Taylor WF, Ivins JC, Pritchard DJ, Soule EH. A prospective randomized study of the efficacy of routine elective lymphadenectomy in management of malignant melanoma: preliminary results. Cancer 1978;41:948–956.

    PubMed  CAS  Google Scholar 

  13. Sim FH, Taylor WF, Pritchard DJ, Soule EH. Lymphadenectomy in the management of stage I malignant melanoma: a prospective randomized study. Mayo Clin Proc 1986;62:697–705.

    Google Scholar 

  14. Veronesi U, Adamus J, Bandiera DC, et al. Inefficacy of immediate node dissection in stage I melanoma of the skin of the lower extremities. Cancer 1982;49:2420–2430.

    PubMed  CAS  Google Scholar 

  15. Balch CM. The role of elective lymph node dissection in melanoma: rationale, results, and controversies. J Clin Oncol 1988;6:163–172.

    PubMed  CAS  Google Scholar 

  16. Balch CM. Surgical management of melanoma: results of prospective randomized trials. Ann Surg Oncol 1998;5:301–309.

    PubMed  CAS  Google Scholar 

  17. Cascinelli N, Morabito A, Santinami M, MacKie RM, Belli F. Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomized trial. Lancet 1998;351:793–796.

    PubMed  CAS  Google Scholar 

  18. Haddad FF, Stall A, Messina J, et al. The progression of melanoma nodal metastasis is dependent on tumor thickness of the primary lesion. Ann Surg Oncol 1999;6:144–149.

    PubMed  CAS  Google Scholar 

  19. Gershenwald JE, Colome MI, Lee JE, et al. Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. J Clin Oncol 1998;16:2253–2260.

    CAS  PubMed  Google Scholar 

  20. Balch CM. Cutaneous melanoma: prognosis and treatment results worldwide. Semin Surg Oncol 1992;8:400–414.

    PubMed  CAS  Google Scholar 

  21. Meyskens FLJ, Berdeaux DH, Parks B, Tong T, Loescher L, Moon TE. Cutaneous malignant melanoma (Arizona Cancer Center experience). I. Natural history and prognostic factors influencing survival in patients with stage I disease. Cancer 1988;62:1207–1214.

    PubMed  Google Scholar 

  22. Mraz-Gernhard S, Sagebiel RW, Kashani-Sabet M, Miller JR, Leong SPL. Prediction of sentinel lymph node micrometastasis by histological features in primary cutaneous malignant melanoma. Arch Dermatol 1998;134:983–987.

    PubMed  CAS  Google Scholar 

  23. Soong SJ, Shaw HM, Balch CM, McCarthy WH, Urist MM, Lee JY. Predicting survival and recurrence in localized melanoma: a multivariate approach. World J Surg 1992;16:191–195.

    PubMed  CAS  Google Scholar 

  24. Schuchter L, Schultz DJ, Synnestvedt M, et al. A prognostic model for predicting 1-year survival in patients with primary melanoma. Ann Intern Med 1996;125:369–375.

    PubMed  CAS  Google Scholar 

  25. Cascinelli N, Marubini E, Morabito A, Bufalino R. Prognostic factors for stage I melanoma of the skin: a review. Stat Med 1985;4:265–278.

    PubMed  CAS  Google Scholar 

  26. Wanek LA, Elashoff RM, Goradia TM, Morton DL, Cochran AJ. Application of multistage Markov modeling to malignant melanoma progression. Cancer 1994;73:336–343.

    PubMed  CAS  Google Scholar 

  27. Sahin S, Rao B, Kopf AW, et al. Predicting ten-year survival of patients with primary cutaneous melanoma: corroboration of a prognostic model. Cancer 1997;80:1426–1431.

    PubMed  CAS  Google Scholar 

  28. Hein DW, Moy RL. Elective lymph node dissection in stage I malignant melanoma: a meta-analysis. Melanoma Res 1992;2:273–277.

    PubMed  CAS  Google Scholar 

  29. Rompel R, Garbe C, Buttner P, Teichelmann K, Petres J. Role of elective lymph node dissection in stage I malignant melanoma: evaluation by matched pair analysis. Recent Results Cancer Res 1995;139:323–336.

    PubMed  CAS  Google Scholar 

  30. Kuehnl-Petzoldt C, Wiebelt H, Berger H. Prognostic groups of patients with stage I melanoma. Arch Dermatol 1983;119:816–819.

    PubMed  CAS  Google Scholar 

  31. Buttner P, Garbe C, Bertz J, et al. Primary cutaneous melanoma: optimized cutoff points of tumor thickness and importance of Clark’s level for prognostic classification. Cancer 1995;75:2499–2506.

    PubMed  CAS  Google Scholar 

  32. Averbook BJ, Russo LJ, Mansour EG. A long-term analysis of 620 patients with malignant melanoma at a major referral center. Surgery 1998;124:746–756.

    PubMed  CAS  Google Scholar 

  33. Buzaid AC, Ross MI, Balch CM, et al. Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system. J Clin Oncol 1997;15:1039–1051.

    PubMed  CAS  Google Scholar 

  34. Garbe C, Buttner P, Bertz J, et al. Primary cutaneous melanoma: identification of prognostic groups and estimation of individual prognosis for 5093 patients. Cancer 1995;75:2484–2491.

    PubMed  CAS  Google Scholar 

  35. Thorn M, Ponten F, Bergstrom R, Sparen P, Adami HO. Clinical and histopathologic predictors of survival in patients with malignant melanoma: a population-based study in Sweden. J Natl Cancer Inst 1994;86:761–769.

    PubMed  CAS  Google Scholar 

  36. Balch CM, Wilkerson JA, Murad TM, Soong SJ, Ingalls AL, Maddox WA. The prognostic significance of ulceration of cutaneous melanoma. Cancer 1980;45:3012–3017.

    PubMed  CAS  Google Scholar 

  37. Essner R, Conforti A, Kelley MC, et al. Efficacy of lymphatic mapping, sentinel lymphadenectomy, and selective complete lymph node dissection as a therapeutic procedure for early-stage melanoma. Ann Surg Oncol (in press)

  38. Vossaert KA, Silverman MK, Kopf AW, et al. Influence of gender on survival in patients with stage I malignant melanoma. J Am Acad Dermatol 1992;26:429–440.

    Article  PubMed  CAS  Google Scholar 

  39. Chang AE, Karnell LH, Menck HR. The National Cancer Center Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. Cancer 1998;83:1664–1668.

    PubMed  CAS  Google Scholar 

  40. Austin PF, Cruse CW, Lyman G, Schroer K, Glass F, Reintgen DS. Age as a prognostic factor in the malignant melanoma population. Ann Surg Oncol 1994;1:487–494.

    PubMed  CAS  Google Scholar 

  41. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996;14:7–17.

    PubMed  CAS  Google Scholar 

  42. Wallack MK, Sivanandham M, Balch CM, et al. A phase III randomized, double-blind multiinstitutional trial of vaccinia melanoma oncolysate-active specific immunotherapy for patients with stage II melanoma. Cancer 1995;75:35–42.

    Google Scholar 

  43. Balch CM, Durant JR, Bartolucci AA. The impact of surgical quality control in multi-institutional group trials involving adjuvant cancer treatments. Ann Surg 1983;198:164–167.

    PubMed  CAS  Google Scholar 

  44. Morton DL, Wen D-R, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992;127:392–399.

    CAS  PubMed  Google Scholar 

  45. Morton DL, Wanek L, Nizze JA, Elashoff RM, Wong JH. Improved long-term survival after lymphadenectomy of melanoma metastatic to regional nodes. Ann Surg 1991;214:491–501.

    PubMed  CAS  Google Scholar 

  46. Day CLJ, Mihm MCJ, Lew RA, et al. Prognostic factors for patients with clinical stage I melanoma of intermediate thickness (1.51–3.39 mm): a conceptual model for tumor growth and metastasis. Ann Surg 1982;195:35–43.

    Article  PubMed  Google Scholar 

  47. Lock-Andersen J, Hou-Jensen K, Hansen J, Jensen NK, Sogaard H, Andersen PK. Observer variation in histological classification of cutaneous malignant melanoma. Scand J Plast Reconstr Surg Hand Surg 1995;29:141–148.

    PubMed  CAS  Google Scholar 

  48. Corona R, Mele A, Amini M, et al. Interobserver variability on the histopathologic diagnosis of cutaneous melanoma and other pigmented skin lesions. J Clin Oncol 1996;14:1218–1223.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Consortia

Corresponding author

Correspondence to Charles M. Balch MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Balch, C.M., Soong, Sj., Ross, M.I. et al. Long-Term Results of a Multi-Institutional Randomized Trial Comparing Prognostic Factors and Surgical Results for Intermediate Thickness Melanomas (1.0 to 4.0 mm). Ann Surg Oncol 7, 87–97 (2000). https://doi.org/10.1007/s10434-000-0087-9

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10434-000-0087-9

Keywords

Navigation